| Role |
Name |
Disclosure |
Details |
| Author | Fredy J Revilla, MD, Assistant Professor of Neurology, Head of Division of Movement Disorders, Department of Neurology, University of Cincinnati College of Medicine, Cincinnati Veterans Affairs Medical Center | Nothing to disclose | Details | | Coauthor | Jaime Grutzendler, MD, Assistant Professor, Department of Neurology and Physiology, Northwestern University School of Medicine | Nothing to disclose | Details | | Medical Editor | Robert A Hauser, MD, MBA, Professor of Neurology, Molecular Pharmacology and Physiology, Director, Parkinson's Disease and Movement Disorders Center, University of South Florida; Clinical Chair, Signature Interdisciplinary Program in Neuroscience | Allergan Sales, LLC Bayer Shering Pharma AG Boehringer Ingelheim France Centapharm Genzyme Corporation GlaxoSmithKline IMPAX Laboratories, Inc. Kyowa Pharmaceuticals, Inc. Novartis Pharmaceuticals Corp. Prestwick Pharmaceuticals, Inc. Schering Plough Solvay Pharmeceuticals Teva Neuroscience | Details | | Pharmacy Editor | Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine | Nothing to disclose | Details | | Managing Editor | Richard J Caselli, MD, Professor, Department of Neurology, Mayo Medical School, Rochester, MN; Chair, Department of Neurology, Mayo Clinic of Scottsdale | Nothing to disclose | Details | | Chief Editor | Selim R Benbadis, MD, Professor, Director of Comprehensive Epilepsy Program, Departments of Neurology and Neurosurgery, University of South Florida School of Medicine, Tampa General Hospital | Nothing to disclose | Details |
Contributor Disclosure
Contributor:
|
Contributor Disclosure: |
| Jaime Grutzendler, Coauthor |
The contributor discloses no conflict of interest. |
Contributor Disclosure
Contributor:
|
Contributor Disclosure: |
| Richard J Caselli, Managing Editor |
The contributor discloses no conflict of interest. |
|